Acute leukemia therapy at a crossroads: from conventional chemotherapy to the era of precision medicine.
Since the discovery of cytotoxic agents in the mid-20th century, acute leukemia has consistently served as a model for oncology research. In this review, we describe the evolution of leukemia therapy-highlighting historical trajectory across AML, APL, and ALL from uniform cytotoxic chemotherapy to molecularly targeted agents, antibody-based therapies, and chemo-free paradigms, while outlining future perspectives for precision hematology.
Since the discovery of cytotoxic agents in the mid-20th century, acute leukemia has consistently served as a model for oncology research. In this review, we describe the evolution of leukemia therapy-highlighting historical trajectory across AML, APL, and ALL from uniform cytotoxic chemotherapy to molecularly targeted agents, antibody-based therapies, and chemo-free paradigms, while outlining future perspectives for precision hematology.
What the study was
- Study design
- Review
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Biochem Pharmacol
Why it surfaced
Matched watchlist topic(s): Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma). Study design: Review. Score 8/10. 🟠 Novel or significantly improved treatment.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.